TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo
Brief Summary: The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain scores recorded in the participant's diary in participants with diabetic peripheral neuropathic pain.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: Nortriptyline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nortriptyline Hydrochloride | Arm Label: Placebo (for nortriptyline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for nortriptyline) | Intervention Type: DRUG; Name: Nortriptyline Hydrochloride; Assigned to Arm(s): Nortriptyline | Intervention Type: DRUG; Name: Placebo (for nortriptyline); Assigned to Arm(s): Placebo (for nortriptyline)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
Brief Summary: The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.


Options:
A: Arm Label: RITUXIMAB; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticosteroids and Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): RITUXIMAB | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroids and Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Corticosteroids and Cyclophosphamide
B: Arm Label: Rituximab Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: Cyclosporine Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclosporine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab Treatment Arm | Intervention Type: DRUG; Name: Cyclosporine; Assigned to Arm(s): Cyclosporine Treatment Arm
C: Arm Label: prednisone; Type: N/A; Interventions: N/A | Arm Label: prednisone and anti-virus; Type: N/A; Interventions: N/A
D: Arm Label: active comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | Arm Label: experimental; Type: EXPERIMENTAL; Interventions: Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Intervention Type: DRUG; Name: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Assigned to Arm(s): active comparator | Intervention Type: DRUG; Name: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); Assigned to Arm(s): experimental

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy: A Randomized Trial
Brief Summary: The aim of this study was to evaluated the advantages of routine application of the anterior approach in patients scheduled to right hepatectomy or extended right hepatectomy, without infiltration of segment 1, inferior vena cava or main bile duct.


Options:
A: Arm Label: Clamp-Crush technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crush technique | Arm Label: Stapler hepatectomy; Type: EXPERIMENTAL; Interventions: Procedure: Stapler hepatectomy | Intervention Type: PROCEDURE; Name: Clamp-Crush technique; Assigned to Arm(s): Clamp-Crush technique | Intervention Type: PROCEDURE; Name: Stapler hepatectomy; Assigned to Arm(s): Stapler hepatectomy
B: Arm Label: ANTERIOR APPROACH; Type: EXPERIMENTAL; Interventions: Procedure: RIGHT HEPATECTOMY WITH CLASSIC APPROACH | Intervention Type: PROCEDURE; Name: RIGHT HEPATECTOMY WITH CLASSIC APPROACH; Assigned to Arm(s): ANTERIOR APPROACH
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Normovolemic Hemodilution (ANH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of care | Intervention Type: PROCEDURE; Name: Normovolemic Hemodilution (ANH); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard of care; Assigned to Arm(s): 2
D: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SUUBI MAKA ("Hope for Families"): A Family-Based Economic Empowerment Model for Orphaned Children in Uganda
Brief Summary: The overall goal of SUUBI-MAKA is to further develop and preliminarily examine a family economic empowerment intervention that creates economic opportunities (specifically Children Development Accounts) for families in Uganda who are caring for children orphaned due to the AIDS pandemic, and to lay groundwork for a bigger study with practice and policy implications for Sub-Saharan Africa.


Options:
A: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Other: EUC | Arm Label: THPP-P; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-P, Other: EUC | Intervention Type: BEHAVIORAL; Name: THPP-P; Assigned to Arm(s): THPP-P | Intervention Type: OTHER; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC), THPP-P
B: Arm Label: Sinovuyo Caring Families Programme; Type: EXPERIMENTAL; Interventions: Behavioral: Sinovuyo Caring Families Programme | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sinovuyo Caring Families Programme; Assigned to Arm(s): Sinovuyo Caring Families Programme
C: Arm Label: Waitlist+EducAid; Type: ACTIVE_COMPARATOR; Interventions: Other: EducAid educational programming | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: YRI only; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Arm Label: YRI+EducAid; Type: EXPERIMENTAL; Interventions: Behavioral: YRI, Other: EducAid educational programming | Intervention Type: BEHAVIORAL; Name: YRI; Assigned to Arm(s): YRI only, YRI+EducAid | Intervention Type: OTHER; Name: EducAid educational programming; Assigned to Arm(s): Waitlist+EducAid, YRI only, YRI+EducAid
D: Arm Label: SUUBI-MAKA; Type: EXPERIMENTAL; Interventions: Behavioral: Suubi-Maka ('Hope for Families') | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Suubi-Maka ('Hope for Families'); Assigned to Arm(s): SUUBI-MAKA | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Probiotics in Childhood Abdominal Pain
Brief Summary: The purpose of this study is to assess the effect of probiotics in childhood recurrent abdominal pain. Patients will be randomly assigned to receive L. reuteri or placebo for 4 weeks with a follow up phase of additional 4 weeks.


Options:
A: Arm Label: Probiotics supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG (probiotic ) | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG (probiotic ); Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Drug: Glucomannan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fiber; Type: EXPERIMENTAL; Interventions: Behavioral: Elimination Diet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Elimination Diet | Intervention Type: BEHAVIORAL; Name: Elimination Diet; Assigned to Arm(s): Fiber, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
Brief Summary: This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \>50% (\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Screening for intimate partner violence | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Screening for intimate partner violence; Assigned to Arm(s): 1
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
C: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only
D: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
Brief Summary: This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \>50% (\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.


Options:
A: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: PR OROS Methylphenidate | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PR OROS Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
B: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only
C: Arm Label: TAU only; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Outpatient Treatment | Arm Label: TMAC only; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling | Arm Label: TMAC plus; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling plus incentives | Intervention Type: OTHER; Name: Intensive Outpatient Treatment; Assigned to Arm(s): TAU only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling; Assigned to Arm(s): TMAC only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling plus incentives; Assigned to Arm(s): TMAC plus
D: Arm Label: Methadone Maintenance; Type: EXPERIMENTAL; Interventions: Behavioral: Methadone Maintenance | Arm Label: Methadone Detoxification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Linkage to methadone maintenance | Intervention Type: BEHAVIORAL; Name: Methadone Maintenance; Assigned to Arm(s): Methadone Maintenance | Intervention Type: BEHAVIORAL; Name: Linkage to methadone maintenance; Assigned to Arm(s): Methadone Detoxification

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Short Bursts of Body Weight Supported Treadmill Training vs. Overground Walking Training in Persons With Chronic Stroke
Brief Summary: The purpose of this study is to compare two different walking training programs for persons with chronic stroke.


Options:
A: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program
B: Intervention Type: PROCEDURE; Name: exercise therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: walking rehabilitation; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: intensified gait trainer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: intensified gait trainer | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intensified gait trainer; Assigned to Arm(s): 1, 2
D: Arm Label: Body weight supported treadmill training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Body weight supported treadmill training | Arm Label: Overground walking training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Overground walking training | Intervention Type: BEHAVIORAL; Name: Body weight supported treadmill training; Assigned to Arm(s): Body weight supported treadmill training | Intervention Type: BEHAVIORAL; Name: Overground walking training; Assigned to Arm(s): Overground walking training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy
Brief Summary: Pregnant women are randomised to supplementation with fish oil, methyl tetrahydro folic acid, both or a placebo during the second half of pregnancy. Biochemical measures are determined in maternal blood during pregnancy and in cord blood.

Non invasive follow up examinations of infants at ages 4, 5.5, 6.5, 7.5, 8, 9 and 9.5 years focus on long term effects of supplementation anthropometric development, neurological development and allergy risk.


Options:
A: Arm Label: DHA supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA Supplementation | Arm Label: Control (milk without DHA); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control (milk without DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplementation; Assigned to Arm(s): DHA supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (milk without DHA); Assigned to Arm(s): Control (milk without DHA)
B: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
C: Arm Label: fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil | Arm Label: folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folate | Arm Label: fish oil + folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil + folate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: folate; Assigned to Arm(s): folate | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil + folate; Assigned to Arm(s): fish oil + folate | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy
Brief Summary: Pregnant women are randomised to supplementation with fish oil, methyl tetrahydro folic acid, both or a placebo during the second half of pregnancy. Biochemical measures are determined in maternal blood during pregnancy and in cord blood.

Non invasive follow up examinations of infants at ages 4, 5.5, 6.5, 7.5, 8, 9 and 9.5 years focus on long term effects of supplementation anthropometric development, neurological development and allergy risk.


Options:
A: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
B: Arm Label: DHA arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): DHA arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo arm
C: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
D: Arm Label: fish oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil | Arm Label: folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folate | Arm Label: fish oil + folate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil + folate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: folate; Assigned to Arm(s): folate | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil + folate; Assigned to Arm(s): fish oil + folate | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo

Answer: D